



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Date: February 4, 2020

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

To
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Reg: Security Code No. 530233:

Sub: Outcome of the Board Meeting dated February 4, 2020:

Dear Sir / Ma'am,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. **Tuesday, February 4, 2020**), has approved the Unaudited Financial Results for the quarter ended December 31, 2019 as recommended by the Audit Committee along with the Limited Review Report received from the Statutory Auditors.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the quarter ended December 31, 2019.
- Limited Review Report received from the Statutory Auditor of the Company.

The Meeting of the Board commenced at 4.30 p.m. and concluded at 5.35 p.m. The results will be published in the newspaper pursuant to Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully,
For AURO LABORATORIES LIMITED


SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796

Encl.: as above

AURO LABORATORIES LIMITED
CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR
BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax: +91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

PART - I

(Rs. in Lakhs except EP)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2019

Sr. No.	Particulars	3 Months ended	3 Months ended	Corresponding 3 Months ended in the Previous Year	Nine month Ended		Previous Year Ended
		31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)
1	Income from Operations						
	(a) Net Sales/Income from Operations (Net of excise duty)	954.40	1110.27	1227.61	3,436.23	3,529.30	4,682.31
2	Other Income	10.76	22.41	7.28	59.07	36.48	95.82
3	Total Revenue (1 + 2)	965.16	1,132.68	1,234.89	3,495.30	3,565.78	4,778.13
4	Expenses						
	a. Consumption of raw material	350.35	594.57	793.71	1,974.51	2,392.68	3,013.82
	b. Purchase of Stock-in-trade	-	1.65	-	25.75	1.04	24.91
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	95.32	(38.30)	(61.63)	(70.79)	(167.94)	(176.59)
	d. Employee benefits expense	136.68	103.3	96.67	342.63	274.75	407.07
	e. Finance Cost	9.82	11.45	18.01	36.79	59.65	72.22
	f. Depreciation and amortisation expenses	28.00	26.00	28.00	79.00	78.50	100.92
	g. Other Expenses	213.6	230.57	175.61	620.26	551.36	728.89
	Total Expenses (4)	833.77	929.24	1,050.37	3,008.15	3,190.04	4,171.24
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	131.39	203.44	184.52	487.15	375.74	606.89
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	131.39	203.44	184.52	487.15	375.74	606.89
8	Extraordinary Items	-	-	-	-	-	-
9	Profit / (Loss) before tax (7 ± 8)	131.39	203.44	184.52	487.15	375.74	606.89
10	Tax expense	-	-	-	-	-	-
	(a) Current tax expenses for current year	27.55	58.92	46.13	128.36	93.94	161.69
	(b) MAT credit (where applicable)	-	-	-	-	-	-
	(c) Deffered tax	-	-	-	-	-	5.25
11	Profit / (Loss) for the period from continuing operation (9 ± 10)	103.84	144.52	138.39	358.79	281.80	439.95
12	Profit / (Loss) for discontinuing operations	-	-	-	-	-	-
13	Tax expense of discontinuing operations	-	-	-	-	-	-
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	103.84	144.52	138.39	358.79	281.80	439.95
15	Other Comprehensive Income	25.16	(6.93)	(1.34)	25.16	(1.34)	8.11
16	Total Comprehensive Income for the period (14 ± 15)	129.00	137.59	137.05	383.95	280.46	448.06
17	Paid-up equity share capital	623.25	623.25	623.25	623.25	623.25	623.25
	(Face value of Rs. 10 each)						
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year)	-	-	-	-	-	1,117.95
19	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):						
	(a) Basic	1.67	2.32	2.22	5.76	4.52	7.06
	(b) Diluted	1.67	2.32	2.22	5.76	4.52	7.06

Notes:

- 1) The above unaudited financial results for the quarter ended 31st December, 2019 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 4th February, 2020.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) Limited review has been carried out by the Statutory Auditors of the Company.

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

(Signature)

SIDDHARTHA DEORAH

WHOLE TIME DIRECTOR

DIN NO. 00230796

Place : Mumbai

Date : 04.02.2020

To,
The Board of Directors,
Auro Laboratories Limited.

KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS


We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter ended December 31, 2019, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants



Sampat Khurdia
Partner

Membership No. 033615

Firm Reg. No. 120263W

Place: Mumbai

Date: February 4, 2020.

